lutetium Lu 177 bombesin

177Lu-BN is a targeted radiopharmaceutical composed of the beta-emitting radioisotope Lutetium-177 conjugated to a bombesin (BN) peptide analog, typically via a chelator such as DOTA. It is designed to specifically target the gastrin-releasing peptide receptor (GRPR), a member of the bombesin receptor family that is frequently overexpressed in various human malignancies, including prostate, breast, and small cell lung cancers. The bombesin peptide acts as a targeting vector, delivering the cytotoxic beta radiation of Lutetium-177 directly to tumor cells, leading to DNA damage and cell death. Additionally, the gamma emission of Lutetium-177 allows for molecular imaging via SPECT, making 177Lu-BN a potential theranostic agent for the management of GRPR-positive tumors.

Other names

177Lu-BombesinLutetium-177 BombesinLutetium177 BombesinLutetium 177 Bombesin